Your browser is no longer supported. Please, upgrade your browser.
MRK Merck & Co. Inc. daily Stock Chart
Merck & Co. Inc.
IndexDJIA S&P500 P/E35.98 EPS (ttm)1.64 Insider Own0.04% Shs Outstand2.77B Perf Week-1.36%
Market Cap163.17B Forward P/E15.69 EPS next Y3.75 Insider Trans-22.65% Shs Float2.77B Perf Month3.12%
Income4.62B PEG7.06 EPS next Q0.91 Inst Own74.90% Short Float1.10% Perf Quarter4.51%
Sales39.39B P/S4.14 EPS this Y-61.60% Inst Trans0.05% Short Ratio3.43 Perf Half Y16.49%
Book/sh15.79 P/B3.73 EPS next Y0.81% ROA4.60% Target Price61.85 Perf Year4.80%
Cash/sh4.67 P/C12.61 EPS next 5Y5.10% ROE10.20% 52W Range44.16 - 59.95 Perf YTD13.25%
Dividend1.84 P/FCF28.04 EPS past 5Y41.50% ROI6.40% 52W High-1.88% Beta0.66
Dividend %3.13% Quick Ratio1.30 Sales past 5Y-3.00% Gross Margin62.80% 52W Low33.19% ATR0.78
Employees68000 Current Ratio1.60 Sales Q/Q-1.20% Oper. Margin18.20% RSI (14)58.48 Volatility1.07% 1.21%
OptionableYes Debt/Eq0.59 EPS Q/Q20.60% Profit Margin11.70% Rel Volume0.71 Prev Close58.79
ShortableYes LT Debt/Eq0.54 EarningsJul 29 BMO Payout110.40% Avg Volume8.84M Price58.82
Recom2.50 SMA200.95% SMA503.77% SMA20010.83% Volume6,262,375 Change0.05%
Apr-06-16Initiated Societe Generale Buy $80
Jan-27-16Downgrade BofA/Merrill Buy → Neutral
Dec-01-15Upgrade Barclays Equal Weight → Overweight $64 → $66
Nov-24-15Initiated Berenberg Hold
Nov-17-15Reiterated Argus Buy $70 → $65
Jun-17-15Initiated Piper Jaffray Neutral
Apr-29-15Reiterated UBS Buy $64 → $68
Apr-29-15Reiterated Argus Buy $66 → $70
Apr-30-14Reiterated Argus Buy $62 → $66
Apr-11-14Reiterated MKM Partners Buy $64 → $70
Feb-05-14Reiterated Argus Buy $54 → $62
Jan-14-14Reiterated MKM Partners Buy $59 → $64
Jun-03-13Reiterated MKM Partners Buy $54 → $59
Apr-15-13Reiterated Barclays Overweight $45 → $60
Feb-04-13Reiterated MKM Partners Buy $51 → $52
Feb-04-13Reiterated Barclays Overweight $46 → $45
Nov-20-12Upgrade MKM Partners Neutral → Buy $47 → $51
Oct-17-12Reiterated MP Advisors Outperform $45 → $50
Jul-30-12Reiterated UBS Buy $45 → $50
Jul-13-12Upgrade MP Advisors Market Perform → Outperform $45
Jul-24-16 07:59AM  The Economy, Interest Rates, Earnings and the Markets
Jul-23-16 11:41AM  In Case You Missed It, 5 New Lung Cancer Drugs Have Been Approved Since October at Motley Fool
Jul-22-16 04:44PM  5 Big Drugmakers Reporting Earnings Next Week
04:11PM  Eli Lilly, J&J, Novo Battle Diabetes -- And Each Other
12:08PM  Merck Presents Data On Its Investigational Once-Daily Formulation Of ISENTRESS
12:07PM  Market Exclusives Inside the FDA: This Week Bezlotoxumab from Merck & Co., Inc. (MRK) at Insider Monkey
07:00AM  Data for Merck's Investigational Once-Daily Formulation of ISENTRESS® (raltegravir) Show That at Week 48, a Regimen Containing the Once-Daily Dosing Formulation... Business Wire
Jul-21-16 05:24PM  More Than 400 Women Are Now Suing Merck for Unequal Pay at Fortune
05:00PM  Merck Animal Health Receives FDA Approval of BRAVECTO® (fluralaner topical solution) for Cats and Dogs Business Wire
04:30PM  Merck Provides Regulatory Update on Biologics Licensing Application for Investigational Agent Bezlotoxumab Business Wire
04:20PM  Sorry, You Can't Buy This Hot Biotech -- At Least Not Directly at Motley Fool
01:49PM  How Did Novartiss 2Q16 Earnings Stand up to Analyst Estimates?
12:10PM  These 5 Big Stocks Are Breaking Out This Summer
09:03AM  These 5 Healthcare Stocks Have Huge Dividend Yields -- Are Any Worth Buying? at Motley Fool
Jul-20-16 03:00PM  Six Major Biotech Acquisitions You Could See In 2016 (Part 1) at Forbes
11:17AM  U.S. healthcare stock bulls look past political risks
07:47AM  What's behind heavy put volume in Merck
Jul-19-16 01:15PM  Merck & Co., Inc. (MRK) and OpGen Inc (OPGN) Are Quietly Changing The Infectious Disease Landscape at Insider Monkey
12:00PM  Why a Trump Win Could Be Good News for Pfizer, IBM at
09:23AM  Merck KGaA's Multiple Sclerosis Drug under Review in EU
08:22AM  5 Big Pharma Stocks Struggling to Raise Their Dividends at Motley Fool
07:20AM  Cambridges Jounce announces hefty $2.5B deal with Celgene for cancer drugs at
Jul-18-16 02:58PM  Here's When You Should Buy Merck
11:06AM  Analyst: Merck's Fundamentals Don't Warrant Current Valuation
09:41AM  Merck (MRK) Stock Slides, BMO Downgrades
09:08AM  Ligand Pharmaceuticalss Portfolio Pyramid as Its Valuation Catalyst
08:15AM  Analysts' Actions -- Groupon, Humana, Monster, Merck and More
Jul-17-16 05:54AM  Herd Mentality
Jul-15-16 05:29PM  Two of the Worlds Best-Selling Drugs Are Headed for a Lot More Competition at Fortune
01:08PM  5 Overvalued Dow Components
10:36AM  Gilead's HCV Drug Epclusa Gets Regulatory Nod in Canada
09:27AM  Is Advaxis' Stock Now a Bargain? at Motley Fool
Jul-14-16 07:01PM  UK charity pockets $150 mln from Merck cancer immunotherapy drug
03:10PM  Here's where Merck's new Cambridge research facility will be located at
Jul-13-16 03:22PM  Merck to Axe Jobs As Part of New Research Focus at Fortune
09:15AM  Short Sellers Run for Cover From Major Pharma at 24/7 Wall St.
07:30AM  Merck to open new Cambridge facility for microbiome research this year at
06:35AM  Big Pharma eyes Bay Area, Boston expansions as it cuts R&D elsewhere at
Jul-12-16 05:06PM  These Four Drugs Were Withdrawn by the CHMP in June
05:06PM  The CHMP Just Recommended the Extension of These Drugs Therapeutic Indications
02:59PM  Merck (MRK) Stock Gaining, Cutting Research Jobs
02:52PM  [$$] Merck to Cut Research Jobs at Three East-Coast Sites at The Wall Street Journal
02:44PM  Why Relypsa Stock Is Ripping
10:07AM  Rova-T and Immuno-Oncology Therapies May Be Complementary
Jul-11-16 03:13PM  Why AbbVies Rova-T May Have More Growth Potential than Predicted
09:07AM  Is It Slower Growth for Regenerons Eylea in 2016 and 2017?
01:05AM  A Look at Alexions 2016 Guidance
Jul-10-16 04:07PM  Sentiment Turns On A Dime
Jul-08-16 11:05AM  Dow 30 Stock Roundup: Chevron, Exxon Mobil to Invest in Kazakh Oil Field, Disney to Buy Stake in MLB Advanced Media
07:00AM  Here's what the head of Botox-maker Allergan has to say about drug prices, inversions, and why Carl Icahn is not a threat to his long-term plans
Jul-07-16 10:53AM  Stocks Higher After Release of FOMC Minutes
07:06AM  Whats Really Driving Horizons Valuation?
Jul-06-16 07:07PM  Merck CEO Sells 60,000 Company Shares
04:37PM  Pfizer, Germany's Merck begin large ovarian cancer trial
04:01PM  The 4 Stocks That Lifted the DJIA Wednesday at 24/7 Wall St.
02:32PM  Stocks Pare Gains Post-Fed; Brexit Worries Hurt Airlines, Netflix
12:07PM  Analyst Estimates for Pfizer: Why Should We Take Notice?
09:17AM  3 Vaccine Manufacturers That Investors Should Consider for Their Portfolios
09:03AM  Pfizer And Merck Germany Initiate Phase III Study To Assess Avelumab As First-line Treatment For Ovarian Cancer
07:30AM  [$$] Success of Pharma Immunotherapies Sparks Race Among Biotech Startups at The Wall Street Journal
Jul-05-16 05:07PM  Merck Animal Health Expands in Brazil in Quest to Overtake Zoetis as World Animal Health Leader
04:33PM  How The 'Dogs Of The Dow' Performed In The First Half Of 2016 at Forbes
04:27PM  How Gilead's New Hepatitis C Virus Combination Stacks Up to the Competition at Motley Fool
11:28AM  Merck to Acquire Brazilian Animal Health Company for $400M
09:35AM  Stocks Make Weak Start; Tesla, Illumina Weigh
08:35AM  Juniper Pharmaceuticals Says Merck, Germany, Gets Japan's Regulatory Approval For OneCrinone
Jul-04-16 11:06AM  Insights into Pfizers Profitability and Financial Guidance
07:08AM  Major Change Afoot
Jul-03-16 03:24PM  Better Buy: Celgene Corporation vs. Merck at Motley Fool
11:41AM  These 20 Recently Approved Cancer Drugs Essentially Have 1 Thing in Common at Motley Fool
07:40AM  A Big Breakthrough for Ovarian Cancer Patients at Motley Fool
07:38AM  How Major Pharma Is Faring After the Brexit at 24/7 Wall St.
06:40AM  The Big Loser After Gilead's Latest Approval May Not Be Who You Think (Hint: It's not AbbVie, Inc.) at Motley Fool
Jul-02-16 12:12AM  [$$] Merck to Buy Brazilian Animal-Health Company for $400 Million at The Wall Street Journal
Jul-01-16 03:12PM  Merck (MRK) Stock Climbs After Deal With Brazilian Animal-Health Company
02:39PM  [$$] Merck to Buy Brazilian Animal-Health Company at The Wall Street Journal
12:30PM  Hunting for value
12:05PM  Merck Animal Health Announces Agreement to Acquire Controlling Interest In Brazilian Animal Health Company Vallée S.A. Business Wire
11:07AM  What Are the Benefits of the Novartis-Xencor Alliance to Xencor?
11:06AM  Why AbbVie Expects PTK7 to Enhance Its Oncology Capabilities
10:22AM  Merck CEO Frazier on Immunotherapy, Drug Pricing
08:19AM  Better Buy: GlaxoSmithKline plc vs. Merck at Motley Fool
05:30AM  Results of Pivotal TAILOR Study Confirm Addition of Erbitux to FOLFOX Significantly Improves Outcomes in RAS Wild-Type Metastatic Colorectal Cancer CNW Group
Jun-30-16 04:06PM  What Are Analysts Thinking about Novo Nordisk?
03:54PM  What Is Xencors XmAb Technology?
03:07PM  What the CHMP Just Recommended for Alkems Riluzole Alkem
10:32AM  Merck And Premier Join Hands To Prevent Fractures For Osteoporosis Patients
08:31AM  Merck and Premier Inc. Collaborate to Prevent Fractures for Osteoporosis Patients Business Wire
Jun-29-16 04:01PM  The 4 Stocks That Boosted the Dow Wednesday at 24/7 Wall St.
03:30PM  $200M deal: Merck & Mass. firm to develop personalized cancer vaccines at
02:52PM  These companies hope to deliver a blockbuster Alzheimers drug
12:12PM  Long-term Brexit Fallout May Take a Toll on These Healthcare Stocks
11:35AM  Dow surges 200 points as market tries to shake off Brexit fear at MarketWatch
09:28AM  Stock Futures Notch Higher; Nike Reverses, Climbs
09:00AM  Research Report Initiated on Select Major Drug Manufacturers Equities
07:00AM  Merck and Moderna Announce Strategic Collaboration to Advance Novel mRNA-Based Personalized Cancer Vaccines with KEYTRUDA® (pembrolizumab) for the Treatment of Multiple Types of Cancer Business Wire
Jun-28-16 06:40PM  The FDA Unsurprisingly Approves Gilead's New Hepatitis C Drug. Now What? at Motley Fool
04:19PM  FDA approves first pill to treat all forms of hepatitis C
02:28PM  Gilead Sciences: Dominating at
09:14AM  Merck & Co., Inc. breached its 50 day moving average in a Bearish Manner : MRK-US : June 28, 2016
Merck & Co., Inc. provides health care solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also provides neuromuscular blocking agents for use in surgery; anti-bacterial products for skin and skin structure infections; cholesterol modifying medicines; non-sedating antihistamine; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; and prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it provides antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics for the treatment of C. difficile, and vaccines against bacterial and viral disease in fish. Additionally, the company offers companion animal products, such as ointments for acute and chronic otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; chewable tablets to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FRAZIER KENNETH CChairman, President & CEOJul 05Option Exercise51.0227,6211,409,223550,098Jul 05 12:56 PM
FRAZIER KENNETH CChairman, President & CEOJul 05Sale58.0027,6211,602,018522,477Jul 05 12:56 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 05Sale57.9945,0002,609,33087,151Jul 05 12:56 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 01Option Exercise40.7030,0001,221,000162,151Jul 01 01:13 PM
Schechter Adam HEVP & Pres-Global Human HealthJul 01Option Exercise44.3050,0002,215,00050,000Jul 01 01:13 PM
FRAZIER KENNETH CChairman, President & CEOJul 01Option Exercise51.0232,3791,651,977554,856Jul 05 12:56 PM
FRAZIER KENNETH CChairman, President & CEOJul 01Sale58.0032,3791,877,982522,477Jul 05 12:56 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 01Sale57.4930,0001,724,553132,151Jul 01 01:13 PM
Schechter Adam HEVP & Pres-Global Human HealthJul 01Sale57.6950,0002,884,4150Jul 01 01:13 PM
Golestani ClarkEVP & Chief Info OfficerMay 20Option Exercise44.9838,6471,738,34255,730May 20 02:34 PM
Golestani ClarkEVP & Chief Info OfficerMay 20Sale54.8038,6472,117,85617,083May 20 02:34 PM
Golestani ClarkEVP & Chief Info OfficerMay 19Sale54.551,23067,09717,083May 20 02:34 PM
Holston Michael JEVP, General CounselMay 10Option Exercise44.58100,0214,458,989164,301May 12 11:39 AM
Holston Michael JEVP, General CounselMay 10Sale54.50100,0215,451,14564,280May 12 11:39 AM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerMay 06Option Exercise0.003,335025,928May 09 04:21 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 06Option Exercise0.004,002040,221May 09 04:21 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 06Option Exercise0.002,001015,375May 09 04:21 PM
PERLMUTTER ROGER MExe V-P & Pres, MRLMay 06Option Exercise0.0044,464094,899May 09 04:21 PM
Chattopadhyay SanatExe V-P & Pres. MMDMay 06Option Exercise0.004,002033,430May 09 04:20 PM
HARRISON WILLIAM B JRDirectorApr 13Option Exercise34.445,000172,20016,400Apr 13 03:03 PM
WEEKS WENDELL PDirectorNov 04Option Exercise34.445,000172,2005,100Nov 04 04:37 PM
WEEKS WENDELL PDirectorNov 04Sale55.535,000277,669100Nov 04 04:37 PM
FRAZIER KENNETH CChairman, President & CEOOct 29Option Exercise35.0918,666654,990456,902Oct 30 04:58 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerOct 29Option Exercise36.5637,3131,364,16357,008Oct 29 04:23 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerOct 29Sale55.0837,3132,055,33419,695Oct 29 04:23 PM
FRAZIER KENNETH CChairman, President & CEOOct 29Sale54.6918,6661,020,758438,236Oct 30 04:58 PM
WENDELL PETER CDirectorOct 28Option Exercise34.445,000172,2006,000Oct 28 02:44 PM
WENDELL PETER CDirectorOct 28Sale54.855,000274,2371,000Oct 28 02:44 PM
Holston Michael JEVP, General CounselAug 01Option Exercise0.0022,584062,584Aug 04 02:41 PM
Golestani ClarkEVP & Chief Info OfficerJul 31Option Exercise39.8335,5421,415,54643,994Aug 04 02:41 PM
Golestani ClarkEVP & Chief Info OfficerJul 31Sale59.0931,8311,880,80512,163Aug 04 02:41 PM